Latest research on solifenacin succinate

Solifenacin (rINN), marketed as solifenacin succinate under the trade name Vesicare, is a urinary antispasmodic of the anticholinergic class. It is used in the treatment of overactive bladder with urge incontinence. [Wikipedia]

Latest findings

solifenacin succinate is an orally administered urinary antispasmodic anticholinergic drug. [source, 2011]
The chemical name of solifenacin succinate is 1-azabicyclo [2.2.2] octan-8-yl (1s)-1-phenyl-3,4-dihydro-1h-isoquinoline-2-carboxylate Butanedioic acid. [source, 2011]
A literature survey reveals one semi-micro high-performance liquid chromatography (HPLC) method[4] and one simultaneous liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS / MS) method[5] for the determination of solifenacin succinate in plasma. [source, 2011]
There are no spectrophotometric methods reported for the estimation of solifenacin succinate in the pharmaceutical dosage form. [source, 2011]
Thus, efforts are being made to develop a fast, selective, and sensitive analytical method for the estimation of solifenacin succinate in its tablet formulations. [source, 2011]
solifenacin succinate is only available in the form of an oral tablet. [source, 2011]
solifenacin succinate supplied by BePharm, Ltd. [source, 2011]
The tablets of solifenacin succinate were procured from a local pharmacy. [source, 2011]
A standard solution of solifenacin succinate was prepared by dissolving 10 mg in 100 ml of double distilled water, to give a stock solution of concentration 100 μg/ml of the drug. [source, 2011]
Recovery studies were carried out for both the developed methods by the addition of a known amount of standard drug solution of solifenacin succinate to a pre-analyzed tablet sample solution, at three different concentration levels. [source, 2011]